On May 23rd, Cynthia L. VERST, President of R&D Solutions Design and Delivery Innovation at IQVIA, stated at the Zhangjiang Science and Technology Innovation Salon Global Innovation Leaders session that by the end of 2024, 30% of clinical trials will come from China, 35% from the United States, and a small portion from Europe. The 30% in China represents a significant increase and is growing every year. We see that China's overall development rate globally far exceeds that of the past
